CMRX vs. ABBV

In the year-to-date period, CMRX achieves a 145.40% return, which is significantly higher than ABBV's 12.41% return. Over the past 10 years, CMRX has underperformed ABBV with an annualized return of -13.61%, while ABBV has yielded a comparatively higher 16.44% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Chimerix, Inc. (CMRX) and AbbVie Inc. (ABBV). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current CMRX Sharpe Ratio is 3.51, which is higher than the ABBV Sharpe Ratio of 0.95. The chart below compares the historical Sharpe Ratios of CMRX and ABBV, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

CMRX has not paid dividends to shareholders, while ABBV's dividend yield for the trailing twelve months is around 3.25%.

The maximum CMRX drawdown since its inception was -98.66%, which is greater than ABBV's maximum drawdown of -45.09%. Use the drawdown chart below to compare losses from any high point for CMRX and ABBV. For additional features, visit the drawdowns tool.

The current volatility for Chimerix, Inc. (CMRX) is 0.43%, while AbbVie Inc. (ABBV) has a volatility of 13.30%. This indicates that CMRX experiences smaller price fluctuations and is considered to be less risky than ABBV based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Chimerix, Inc. and AbbVie Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.